{{Rsnum
|rsid=4909189
|Gene=PTPRN2
|Chromosome=7
|position=158344294
|Orientation=plus
|GMAF=0.3012
|Gene_s=PTPRN2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 58.0 | 33.9 | 8.0
| HCB | 57.7 | 31.4 | 10.9
| JPT | 57.5 | 39.8 | 2.7
| YRI | 26.0 | 47.3 | 26.7
| ASW | 36.8 | 38.6 | 24.6
| CHB | 57.7 | 31.4 | 10.9
| CHD | 56.9 | 39.4 | 3.7
| GIH | 73.3 | 25.7 | 1.0
| LWK | 28.2 | 50.0 | 21.8
| MEX | 63.8 | 34.5 | 1.7
| MKK | 32.1 | 48.1 | 19.9
| TSI | 51.0 | 44.1 | 4.9
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=22952603
  |Trait=Response to amphetamines
  |Title=Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13).
  |RiskAllele=
  |Pval=3E-6
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{on chip | Affy GenomeWide 6}}